Melatonin receptor and KATP channel modulation in experimental vascular dementia

Physiology and Behavior

Volumn 142, Issue , 2015, Pages 66-78

  Singh, Prabhat ^a   Gupta, Surbhi ^a   Sharma, Bhupesh ^a,b  

^a BHARAT INSTITUTE OF TECHNOLOGY   (India)

^b Dilshad Garden   (India)

Author keywords

Acetylcholinesterase; Agomelatine; Donepezil; Mitochondrial enzyme complex; Myeloperoxidase; Nicorandil

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; AGOMELATINE; CALCIUM; CATALASE; CYTOCHROME C OXIDASE; DONEPEZIL; GLUTATHIONE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MITOCHONDRIAL ENZYME; MYELOPEROXIDASE; NICORANDIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; SUCCINATE DEHYDROGENASE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; ACETAMIDE DERIVATIVE; MELATONIN RECEPTOR; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CONTROLLED STUDY; ELEVATED PLUS MAZE TEST; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; MALE; MEAN ARTERIAL PRESSURE; MORRIS WATER MAZE TEST; MULTIINFARCT DEMENTIA; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; RENOVASCULAR HYPERTENSION; AGONISTS; ANIMAL; ARTERIAL PRESSURE; BRAIN; DEMENTIA, VASCULAR; DISEASE MODEL; DRUG EFFECTS; HYPERTENSION, RENOVASCULAR; MAZE TEST; METABOLISM; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; SPATIAL MEMORY; WISTAR RAT;

ACETAMIDES; ANIMALS; ARTERIAL PRESSURE; BRAIN; DEMENTIA, VASCULAR; DISEASE MODELS, ANIMAL; HYPERTENSION, RENOVASCULAR; KATP CHANNELS; MALE; MAZE LEARNING; NEUROPROTECTIVE AGENTS; NICORANDIL; NOOTROPIC AGENTS; OXIDATIVE STRESS; RANDOM ALLOCATION; RATS, WISTAR; RECEPTORS, MELATONIN; SPATIAL MEMORY;

EID: 84922311242     PISSN: 00319384     EISSN: 1873507X     Source Type: Journal    
DOI: 10.1016/j.physbeh.2015.02.009     Document Type: Article

References (78)

1. Du J., Ma M., Zhao Q., Fang L., Chang J., Wang Y., et al. Mitochondrial bioenergetic deficits in the hippocampi of rats with chronic ischemia-induced vascular dementia. Neuroscience 2013, 231:345-352.
2. Nural-Guvener H.F., Mutlu N., Gaballa M.A. BACE1 levels are elevated in congestive heart failure. Neurosci. Lett. 2013, 532:7-11.
3. Sharma B., Singh N. Pharmacological inhibition of inducible nitric oxide synthase (iNOS) and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, convalesce behavior and biochemistry of hypertension induced vascular dementia in rats. Pharmacol. Biochem. Behav. 2013, 103:821-830.
4. Sharma B., Sharma P.M. Arsenic toxicity induced endothelial dysfunction and dementia: pharmacological interdiction by histone deacetylase and inducible nitric oxide synthase inhibitors. Toxicol. Appl. Pharmacol. 2013, 273:180-188.
5. Sharma B., Singh N. Salutary effect of NFκB inhibitor and folacin in hyperhomocysteinemia-hyperlipidemia induced vascular dementia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 38:207-215.
6. Sharma B., Singh N. Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berlin) 2011, 215:677-687.
7. Gupta S., Sharma B., Singh P., Sharma B.M. Modulation of transient receptor potential vanilloid subtype 1 (TRPV1) and norepinephrine transporters (NET) protect against oxidative stress, cellular injury, and vascular dementia. Curr. Neurovasc. Res. 2014, 11:94-106.
8. Gupta S., Sharma B. Pharmacological modulation of I(1)-imidazoline and α2-adrenoceptors in sub acute brain ischemia induced vascular dementia. Eur. J. Pharmacol. 2014, 723:80-90.
9. Gava A.L., Peotta V.A., Cabral A.M., Vasquez E.C., Meyrelles S.S. Overexpression of eNOS prevents the development of renovascular hypertension in mice. Can. J. Physiol. Pharmacol. 2008, 86:458-464.
10. Hardeland R. Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment. Aging Dis. 2012, 3:194-225.
11. Ladurelle N., Gabriel C., Viggiano A., Mocaër E., Baulieu E.E., Bianchi M. Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology (Berlin) 2012, 221:493-509.
12. Gupta S., Sharma B. Pharmacological benefits of agomelatine and vanillin in experimental model of Huntington's disease. Pharmacol. Biochem. Behav. 2014, 122:122-135.
13. Aguiar C.C., Almeida A.B., Araújo P.V., Vasconcelos G.S., Chaves E.M., do Vale O.C., et al. Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell. Mol. Neurobiol. 2013, 33:825-835.
14. Molteni R., Macchi F., Zecchillo C., Dell'agli M., Colombo E., Calabrese F., et al. Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine. Eur. Neuropsychopharmacol. 2013, 23:1645-1655.
15. Dagyte G., Trentani A., Postema F., Luiten P.G., Den Boer J.A., Gabriel C., et al. The novel antidepressant agomelatine normalizes hippocampal neuronal activity and promotes neurogenesis in chronically stressed rats. CNS Neurosci. Ther. 2010, 16:195-207.
16. Liu D., Pitta M., Lee J.H., Ray B., Lahiri D.K., Furukawa K., et al. The KATP channel activator diazoxide ameliorates amyloid-β and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. J. Alzheimers Dis. 2010, 22:443-457.
17. Li D., Huang B., Liu J., Li L., Li X. Decreased brain K(ATP) channel contributes to exacerbating ischemic brain injury and the failure of neuroprotection by sevoflurane post-conditioning in diabetic rats. PLoS One 2013, 8:e73334.
18. Xie J., Duan L., Qian X., Huang X., Ding J., Hu G. K(ATP) channel openers protect mesencephalic neurons against MPP+-induced cytotoxicity via inhibition of ROS production. J. Neurosci. Res. 2010, 88:428-437.
19. Kong J., Ren G., Jia N., Wang Y., Zhang H., Zhang W., et al. Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease. Eur. Neurol. 2013, 70:233-241.
20. Virgili N., Espinosa-Parrilla J.F., Mancera P., Pastén-Zamorano A., Gimeno-Bayon J., Rodríguez M.J., et al. Oral administration of the KATP channel opener diazoxide ameliorates disease progression in a murine model of multiple sclerosis. J. Neuroinflammation 2011, 8:149.
21. Yang J.Z., Huang X., Zhao F.F., Xu Q., Hu G. Iptakalim enhances adult mouse hippocampal neurogenesis via opening Kir6.1-composed K-ATP channels expressed in neural stem cells. CNS Neurosci. Ther. 2012, 18:737-744.
22. Sharma B., Singh N. Pitavastatin and 4'-hydroxy-3'-methoxyacetophenone (HMAP) reduce cognitive dysfunction in vascular dementia during experimental diabetes. Curr. Neurovasc. Res. 2010, 7:180-191.
23. Sharma B., Singh N. Defensive effect of natrium diethyldithiocarbamate trihydrate (NDDCT) and lisinopril in DOCA-salt hypertension-induced vascular dementia in rats. Psychopharmacology (Berlin) 2012, 223:307-317.
24. Sharma B., Singh N. Experimental hypertension induced vascular dementia: pharmacological, biochemical and behavioral recuperation by angiotensin receptor blocker and acetylcholinesterase inhibitor. Pharmacol. Biochem. Behav. 2012, 102:101-108.
25. Sharma B., Singh N., Singh M. Modulation of celecoxib- and streptozotocin-induced experimental dementia of Alzheimer's disease by pitavastatin and donepezil. J. Psychopharmacol. 2008, 22:162-171.
26. Dagyte˙ G., Crescente I., Postema F., Seguin L., Gabriel C., Mocaër E., et al. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav. Brain Res. 2011, 218:121-128.
27. Gupta S., Sharma B. Protective effects of phosphodiesterase-1 (PDE1) and ATP sensitive potassium (KATP) channel modulators against 3-nitropropionic acid induced behavioral and biochemical toxicities in experimental Huntington's disease. Eur. J. Pharmacol. 2014, 732:111-122.
28. Jing L., Zhang J.Z., Wang Y.L., Guo F.Y. Over-expression of extracellular signal-regulated kinase in vascular smooth muscle cell of hypertensive rats. Chin. Med. Sci. J. 2006, 21:36-40.
29. Sharma B., Singh N. Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats. Pharmacol. Biochem. Behav. 2011, 100:320-329.
30. Gupta S., Sharma B. Pharmacological benefit of I(1)-imidazoline receptors activation and nuclear factor kappa-B (NF-κB) modulation in experimental Huntington's disease. Brain Res. Bull. 2014, 102:57-68.
31. Frussa-Filho R., Otoboni J.R., Uema F.T., Sá-Rocha L.C. Evaluation of memory and anxiety in rats observed in the elevated plus-maze: effects of age and isolation. Braz. J. Med. Biol. Res. 1991, 24:725-728.
32. Wakisaka Y., Miller J.D., Chu Y., Baumbach G.L., Wilson S., Faraci F.M., et al. Oxidative stress through activation of NAD(P)H oxidase in hypertensive mice with spontaneous intracranial hemorrhage. J. Cereb. Blood Flow Metab. 2008, 28:1175-1185.
33. Singh P., Sharma B., Gupta S., Sharma B.M. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator. Psychopharmacology (Berlin) 2015, 232:465-475.
34. Burtis Carl A., Ashwood Edward R. Mineral and bone metabolism. Tietz Fundamentals of Clinical Chemistry 1996, 685-703. W.B. Saunders and Company, Philadelphia, PA.
35. Lu M., Liu Y.H., Goh H.S., Wang J.J., Yong Q.C., Wang R., Bian J.S. Hydrogen sulfide inhibits plasma renin activity. J. Am. Soc. Nephrol. 2010, 21:993-1002.
36. Botros F.T., Schwartzman M.L., Stier C.T., Goodman A.I., Abraham N.G. Increase in heme oxygenase-1 levels ameliorates renovascular hypertension. Kidney Int. 2005, 68:2745-2755.
37. Hennigan A., Callaghan C.K., Kealy J., Rouine J., Kelly A.M. Deficits in LTP and recognition memory in the genetically hypertensive rat are associated with decreased expression of neurotrophic factors and their receptors in the dentate gyrus. Behav. Brain Res. 2009, 197:371-377.
38. Kishi T., Sunagawa K. Exercise training plus calorie restriction causes synergistic protection against cognitive decline via up-regulation of BDNF in hippocampus of stroke-prone hypertensive rats. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2012, 2012:6764-6767.
39. Choi D.H., Lee K.H., Kim J.H., Seo J.H., Kim H.Y., Shin C.Y., et al. NADPH oxidase 1, a novel molecular source of ROS in hippocampal neuronal death in vascular dementia. Antioxid. Redox Signal. 2014, 21:533-550.
40. Akama K.T., Albanese C., Pestell R.G., Van Eldik L.J. Amyloid beta-peptide stimulates nitric oxide production in astrocytes through an NFkappaB-dependent mechanism. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:5795-5800.
41. Mander P., Brown G.C. Activation of microglial NADPH oxidase is synergistic with glial iNOS expression in inducing neuronal death: a dual-key mechanism of inflammatory neurodegeneration. J. Neuroinflammation 2005, 2:20.
42. Brennan L.A., Kantorow M. Mitochondrial function and redox control in the aging eye: role of MsrA and other repair systems in cataract and macular degenerations. Exp. Eye Res. 2009, 88:195-203.
43. Chan S.L., Baumbach G.L. Nox2 deficiency prevents hypertension-induced vascular dysfunction and hypertrophy in cerebral arterioles. Int. J. Hypertens. 2013, 2013:793630.
44. Kang K.T. Endothelium-derived relaxing factors of small resistance arteries in hypertension. Toxicol. Res. 2014, 30:141-148.
45. Pires P.W., Girgla S.S., McClain J.L., Kaminski N.E., van Rooijen N., Dorrance A.M. Improvement in middle cerebral artery structure and endothelial function in stroke-prone spontaneously hypertensive rats after macrophage depletion. Microcirculation 2013, 20:650-661.
46. Rodrigues S.F., Almeida-Paula L.D., Granger D.N. Synergistic effects of high blood cholesterol and hypertension on leukocyte and platelet recruitment in the cerebral microcirculation. Hypertension 2014, 63:747-752.
47. Helle F., Vågnes Ø.B., Iversen B.M. Angiotensin II-induced calcium signaling in the afferent arteriole from rats with two-kidney, one-clip hypertension. Am. J. Physiol. Renal Physiol. 2006, 291:F140-F147.
48. Wilmott L.A., Thompson L.T. Sex- and dose-dependent effects of post-trial calcium channel blockade by magnesium chloride on memory for inhibitory avoidance conditioning. Behav. Brain Res. 2013, 257:49-53.
49. Kawamoto E.M., Vivar C., Camandola S. Physiology and pathology of calcium signaling in the brain. Front. Pharmacol. 2012, 3:61.
50. Iadecola C., Davisson R.L. Hypertension and cerebrovascular dysfunction. Cell Metab. 2008, 7:476-484.
51. Capone C., Faraco G., Peterson J.R., Coleman C., Anrather J., Milner T.A., et al. Central cardiovascular circuits contribute to the neurovascular dysfunction in angiotensin II hypertension. J. Neurosci. 2012, 32:4878-4886.
52. Soto-Moyano R., Burgos H., Flores F., Valladares L., Sierralta W., Fernández V., et al. Melatonin administration impairs visuo-spatial performance and inhibits neocortical long-term potentiation in rats. Pharmacol. Biochem. Behav. 2006, 85:408-414.
53. Conboy L., Tanrikut C., Zoladz P.R., Campbell A.M., Park C.R., Gabriel C., et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int. J. Neuropsychopharmacol. 2009, 12:329-341.
54. Sansone R.A., Sansone L.A. Agomelatine: a novel antidepressant. Innov. Clin. Neurosci. 2011, 8:10-14.
55. Bari A., Aston-Jones G. Atomoxetine modulates spontaneous and sensory-evoked discharge of locus coeruleus noradrenergic neurons. Neuropharmacology 2013, 64:53-64.
56. Srinivasan V., Pandi-Perumal S.R., Maestroni G.J., Esquifino A.I., Hardeland R., Cardinali D.P. Role of melatonin in neurodegenerative diseases. Neurotox. Res. 2005, 7:293-318.
57. Akpinar A., Uğuz A.C., Naziroğlu M. Agomelatine and duloxetine synergistically modulates apoptotic pathway by inhibiting oxidative stress triggered intracellular calcium entry in neuronal PC12 cells: role of TRPM2 and voltage-gated calcium channels. J. Membr. Biol. 2014, 247:451-459.
58. Yang Y., Duan W., Jin Z., Yi W., Yan J., Zhang S., et al. JAK2/STAT3 activation by melatonin attenuates the mitochondrial oxidative damage induced by myocardial ischemia/reperfusion injury. J. Pineal Res. 2013, 55:275-286.
59. Zhang Y., Cook A., Kim J., Baranov S.V., Jiang J., Smith K., et al. Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2013, 55:26-35.
60. Rezzani R., Porteri E., De Ciuceis C., Bonomini F., Rodella L.F., Paiardi S., Boari G.E., Platto C., Pilu A., Avanzi D., Rizzoni D., Agabiti Rosei E. Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension 2010, 55:1373-1380.
61. Rodella L.F., Favero G., Foglio E., Rossini C., Castrezzati S., Lonati C., Rezzani R. Vascular endothelial cells and dysfunctions: role of melatonin. Front. Biosci. (Elite Ed.) 2013, 5:119-129.
62. Simonini M.V., Polak P.E., Sharp A., McGuire S., Galea E., Feinstein D.L. Increasing CNS noradrenaline reduces EAE severity. J. Neuroimmune Pharmacol. 2010, 5:252-259.
63. Koh P.O. Melatonin regulates the calcium-buffering proteins, parvalbumin and hippocalcin, in ischemic brain injury. J. Pineal Res. 2012, 53:358-365.
64. Campolo M., Ahmad A., Crupi R., Impellizzeri D., Morabito R., Esposito E., et al. Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. J. Endocrinol. 2013, 217:291-301.
65. Windle V., Power A., Corbett D. Norepinephrine depletion facilitates recovery of function after focal ischemia in the rat. Eur. J. Neurosci. 2007, 26:1822-1831.
66. Chuang C.M., Hsieh C.L., Li T.C., Lin J.G. Acupuncture stimulation at Baihui acupoint reduced cerebral infarct and increased dopamine levels in chronic cerebral hypoperfusion and ischemia-reperfusion injured Sprague-Dawley rats. Am. J. Chin. Med. 2007, 35:779-791.
67. Kurihara J., Ochiai N., Kato H. Protection by nicorandil against the dysfunction of the central vagal baroreflex system following transient global cerebral ischaemia in dogs. Br. J. Pharmacol. 1993, 109:1263-1267.
68. Serizawa K., Yogo K., Aizawa K., Tashiro Y., Ishizuka N. Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats. Cardiovasc. Diabetol. 2011, 10:105.
69. Ahmed L.A., El-Maraghy S.A. Nicorandil ameliorates mitochondrial dysfunction in doxorubicin-induced heart failure in rats: possible mechanism of cardioprotection. Biochem. Pharmacol. 2013, 86:1301-1310.
70. Horinaka S., Kobayashi N., Yabe A., Asakawa H., Yagi H., Mori Y., et al. Nicorandil protects against lethal ischemic ventricular arrhythmias and up-regulates endothelial nitric oxide synthase expression and sulfonylurea receptor 2 mRNA in conscious rats with acute myocardial infarction. Cardiovasc. Drugs Ther. 2004, 18:13-22.
71. Wei X.M., Heywood G.J., Di Girolamo N., Thomas P.S. Nicorandil inhibits the release of TNFalpha from a lymphocyte cell line and peripheral blood lymphocytes. Int. Immunopharmacol. 2003, 3:1581-1588.
72. Zhao A.P., Dong Y.F., Liu W., Gu J., Sun X.L. Nicorandil inhibits inflammasome activation and Toll-like receptor-4 signal transduction to protect against oxygen-glucose deprivation-induced inflammation in BV-2 cells. CNS Neurosci. Ther. 2014, 20:147-153.
73. Ran Y.H., Wang H. Iptakalim, an ATP-sensitive potassium channel opener, confers neuroprotection against cerebral ischemia/reperfusion injury in rats by protecting neurovascular unit cells. J. Zhejiang Univ. Sci. B 2011, 12:835-845.
74. Umukoro S., Adewole F.A., Eduviere A.T., Aderibigbe A.O., Onwuchekwa C. Free radical scavenging effect of donepezil as the possible contribution to its memory enhancing activity in mice. Drug Res. (Stuttg) 2014, 64:236-239.
75. Kamat P.K., Tota S., Shukla R., Ali S., Najmi A.K., Nath C. Mitochondrial dysfunction: a crucial event in okadaic acid (ICV) induced memory impairment and apoptotic cell death in rat brain. Pharmacol. Biochem. Behav. 2011, 100:311-319.
76. Kim H.G., Moon M., Choi J.G., Park G., Kim A.J., Hur J., et al. Donepezil inhibits the amyloid-beta oligomer-induced microglial activation in vitro and in vivo. Neurotoxicology 2014, 40:23-32.
77. Akasofu S., Sawada K., Kosasa T., Hihara H., Ogura H., Akaike A. Donepezil attenuates excitotoxic damage induced by membrane depolarization of cortical neurons exposed to veratridine. Eur. J. Pharmacol. 2008, 588:189-197.
78. Fujiki M., Kobayashi H., Uchida S., Inoue R., Ishii K. Neuroprotective effect of donepezil, a nicotinic acetylcholine-receptor activator, on cerebral infarction in rats. Brain Res. 10 2005, 1043:236-241.